Inflammation may help explain why heart attacks and strokes occur in women who do not have any of the usual risk factors, researchers say.

Topline data were announced from a trial evaluating enlicitide in adults with hypercholesterolemia on a moderate or high intensity statin.

MADRID, Spain—Adding evolocumab (Repatha; Amgen) to statin therapy does not lower the risk of saphenous vein graft (SVG) ...

After coronary artery bypass grafting (CABG), evolocumab did not reduce saphenous vein graft disease rates at 2 years ...